A consortium consisting of the largest Japanese companies Mitsui & Co. and Rohto Pharmaceutical Co. is negotiating the acquisition of a controlling stake in Eu Yan Sang International Ltd., a company in the field of traditional Chinese medicine. This is reported by foreign media.
The value of the proposed transaction is $800 million.
The consortium has bypassed other bidders and is currently negotiating the final details of the deal. A final agreement may be signed in the near future, but difficulties in negotiations may lead to further delay. Minority shareholders can also participate in the sale.
In 2023, a consortium that included the investment company Tower Capital Asia Pte, Blanca Investments Pte (a subsidiary of Temasek Holdings Pte) and the family of the founders of the Eu Yan Sang company, considered the possibility of selling a controlling stake. In 2022, Mitsui acquired a stake in Tower Capital Asia, which is an investor of Eu Yan Sang.
Mitsui is a Japanese large universal trading company. The company is part of the Mitsui Group holding. Mitsui owns assets in the fields of electric power, mechanical engineering, finance, chemical, food, textile and other industries.
Rohto Pharmaceutical is a Japanese pharmaceutical company. Rohto is also engaged in the production of high-quality cosmetics and medicines. The headquarters is located in Osaka (Japan).
Eu Yan Sang is a company producing and selling traditional Chinese and other medicines under the EU Yan Sang brand. Eu Yan specializes in traditional Chinese medicine and has 170 retail outlets in Singapore, Malaysia, Hong Kong and Macau, four factories in Hong Kong and Malaysia and 28 TCM clinics in Singapore, Malaysia and Hong Kong.
More news is on the Telegram channel "Mergers and Acquisitions. AK&M».
